Reports Q1 revenue $26.04M vs. $13.09M last year. “We began 2026 with a record quarter, nearly doubling revenue year over year as our NULISA platform gained rapid global traction among leading academic research and biopharma customers,” said Yuling Luo, founder, CEO, and chair of Alamar Biosciences (ALMR). “With our balance sheet significantly strengthened by the proceeds of our recent IPO, we are well-positioned to accelerate adoption of our Precision Proteomics platform and establish a new gold standard in protein detection and analysis.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMR:
- Opening Day: Drone maker AEVEX pops on debut
- Cathie Wood’s ARK Investment buys 537.5K shares of Alamar Biosciences today
- Alamar Biosciences opens at $22.60, IPO priced at $17 per share
- Alamar Biosciences indicated to open at $20, IPO priced at $17
- Alamar Biosciences 11.25M share IPO priced at $17.00